Merck + Co., Inc.

Ucb S.a.

Nathan C Ihle

George D Hartman

Mark E Duggan

Melissa S Egbertson

William F Hoffman

Wasyl Halczenko

James J Perkins

Laura M Turchi

Amy E Krause

John Howard Hutchinson

Steven D Young

David B Whitman

Laura M Vassallo

David A Claremon

Ben C Askew

John S Wai

J Jeffry Howbert

John D Prugh

Cecilia A Hunt

Scott Charles Jeffrey

Randy W Jackson

Karen M Brashear

Kraig M Yager

Laura A Libby

Jim P Boyce

Ihab S Darwish

Dean Maeda

Theodore A Baughman

Benny C Askew

This invention is directed to compound of the following formula (I): wherein R, R, Rand Rare as described herein. These compounds and pharmaceutical compositions containing the compounds are useful in treating inflammatory disorders in mammals.

Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3 and/or &agr;v&bgr;5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

Integrin receptor antagonists

Fibrinogen receptor antagonists having the formula ##STR1## for example ##STR2## which are useful for inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.

Compounds of the following general structure

Guainidino, formamidino, amino and related compounds for inhibiting

This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are .alpha.v.beta.3 antagonists, .alpha.v.beta.5 antagonists or dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.

Integrin antagonists

Fibrinogen receptor antagonists having the structure

Fibrinogen receptor antagonists

Fibrinogen receptor antagonists having the structure, for example, of ##STR1## for example ##STR2##

Pyridyl and naphthyridyl compounds for inhibiting osteoclast-mediated

Fibrinogen receptor antagonists of the formula: ##STR1## such as ##STR2## are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.

Fibrinogen receptor antagonists for inhibiting aggregation of blood

Fibrinogen receptor antagonists having the formula ##STR1## for example ##STR2##

Fibrinogen receptor antagonists of the formula: ##STR1## are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.

Growing community of inventors

Mercer Island, WA, United States of America

Nathan C Ihle